Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Peregrine Pharmaceuticals has reported the positive results of Bavituximab in combination with carboplatin and paclitaxel from a randomised Phase II trial in patients with non-small cell lung cancer (NSCLC).
Subscribe to our email newsletter
Bavituximab, a phosphatidylserine (PS)-targeting monoclonal antibody, acts by targeting PS and thereby enabling the immune system to recognise and fight the tumor.
The randomised Phase II lung cancer trial will compare the overall tumor response rates (ORR) of carboplatin and paclitaxel with or without Bavituximab in 86 patients with front-line, Stage IV metastatic NSCLC.
The study showed that patients treated with Bavituximab combination therapy demonstrated an ORR of 39% compared to 26% in patients treated with carboplatin and paclitaxel alone.
The secondary endpoints of the trial include median progression-free survival (PFS), duration of response, median overall survival (OS), and safety parameters.
Peregrine Pharmaceuticals Medical oncology head Kerstin Menander said the study data will support the PS-targeting platform, indicating Bavituximab’s anti-tumor activity in conjugation with chemotherapy.
The prior Phase II study has demonstrated an ORR data of 43%, median PFS of 6.1 months, and median OS of 12.4 months, when Bavituximab was used with carboplatin and paclitaxel.